Tectonic Therapeutic (TECX) Net Equity Issued and Repurchased (2017 - 2024)
Tectonic Therapeutic (TECX) posted quarterly Net Equity Issued and Repurchased of $4000.0 for Q1 2024, down 69.23% year-over-year from $13000.0 in Q2 2023, and down 94.52% quarter-over-quarter from $73000.0 in Q3 2023.
Powered by 
Analysis
Tectonic Therapeutic (TECX) Net Equity Issued and Repurchased (2017 - 2024) Analysis & Trends
Tectonic Therapeutic (TECX) has reported Net Equity Issued and Repurchased for 7 consecutive years, with $4000.0 the latest figure, recorded in Q1 2024.
- In Q1 2024, Net Equity Issued and Repurchased fell 69.23% year-over-year to $4000.0; the TTM figure through Mar 2024 stood at $77000.0 (up 2.67% YoY), while the FY2023 annual figure was $86000.0, down 57.84% from the prior year.
- Net Equity Issued and Repurchased fell to $4000.0 in Q1 2024 per TECX's latest filing, from $73000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $93.6 million in Q1 2020 and bottomed at -$93.6 million in Q3 2020.
- Historically, Net Equity Issued and Repurchased has averaged $47785.7 across 5 years, with a median of $8500.0 in 2023.
- Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased sank 101.88% — and 2022, when it soared 378.43%.
- Tectonic Therapeutic's Net Equity Issued and Repurchased stood at -$8.0 million in 2020, then surged by 105.19% to $413000.0 in 2021, then tumbled by 99.76% to $1000.0 in 2022, then jumped by 7200.0% to $73000.0 in 2023, then slumped by 94.52% to $4000.0 in 2024.
- Business Quant data shows TECX's Net Equity Issued and Repurchased at $4000.0 in Q1 2024, $73000.0 in Q3 2023, and $13000.0 in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Tectonic Therapeutic | 589.02 Mn | 589.02 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | 4,000.00 |
| Sep 30, 2023 | 73,000.00 |
| Mar 31, 2023 | 13,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | 60,000.00 |
| Jun 30, 2022 | 1,000.00 |
| Mar 31, 2022 | 142,000.00 |
| Dec 31, 2021 | 14.75 Mn |
| Jun 30, 2021 | -153,000.00 |
| Mar 31, 2021 | -51,000.00 |
| Dec 31, 2020 | 70.43 Mn |
| Jun 30, 2020 | 8.13 Mn |
| Mar 31, 2020 | 93.63 Mn |
| Dec 31, 2018 | 45.76 Mn |
| Jun 30, 2018 | -5,000.00 |
| Mar 31, 2018 | 58.26 Mn |
| Dec 31, 2017 | 13.97 Mn |
| Sep 30, 2017 | -20,000.00 |
| Jun 30, 2017 | 16,000.00 |